Journal
MOLECULAR THERAPY
Volume 27, Issue 4, Pages 803-823Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2019.02.019
Keywords
-
Categories
Funding
- European Research Council (ERC) [637752]
- HMZ Privatstiftung
- European Research Council (ERC) [637752] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Protein supplementation therapy using in vitro-transcribed (IVT) mRNA for genetic diseases contains huge potential as a new class of therapy. From the early ages of synthetic mRNA discovery, a great number of studies showed the versatile use of IVT mRNA as a novel approach to supplement faulty or absent protein and also as a vaccine. Many modifications have been made to produce high expressions of mRNA causing less immunogenicity and more stability. Recent advancements in the in vivo lung delivery of mRNA complexed with various carriers encouraged the whole mRNA community to tackle various genetic lung diseases. This review gives a comprehensive overview of cells associated with various lung diseases and recent advancements in mRNA-based protein replacement therapy. This review also covers a brief summary of developments in mRNA modifications and nanocarriers toward clinical translation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available